Design debuts with $45M series A, portfolio against repeat expansions

Design Therapeutics emerged from stealth Friday with a $45 million series A and a portfolio of bifunctional small molecules to treat degenerative disorders caused by nucleotide repeat expansions, starting with Friedreich's ataxia.

SR One led the untranched round with participation from Cormorant Asset Management, Quan Capital and WestRiver Group.

Design was founded in 2017 based on technology developed by co-founder Aseem Ansari

Read the full 604 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE